Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$107.39 USD

107.39
1,645,920

-0.22 (-0.20%)

Updated May 22, 2024 04:00 PM ET

After-Market: $107.37 -0.02 (-0.02%) 5:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ILMN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Illumina, Inc. [ILMN]

Reports for Purchase

Showing records 281 - 300 ( 361 total )

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 281

04/23/2014

Company Report

Pages: 13

Strong 1Q14 Results & Guidance - New Product Stories Shaping Up Nicely - Raising Estimates & PT to $155 from $140 - Valuation Still Uncomfortable

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 282

04/21/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 21

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 283

04/21/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 21

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 284

04/15/2014

Company Report

Pages: 7

1Q14 Preview - Checks Suggest Solid Consumable Trends - Tweaking Revenue Slightly Higher and EPS Lower for New Product Complexities - Maintain N

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 285

03/24/2014

Company Report

Pages: 8

Price: 24.95

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 286

01/29/2014

Company Report

Pages: 12

Solid 4Q13 Call - Warming Up Following New Xten Order & FCF Improvement - Tweaking Estimates & Upping PT

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 287

01/26/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 288

01/23/2014

Company Report

Pages: 9

4Q13 Preview: Expecting a Solid Call in Line with Preannouncement - Raising Estimates and PT to $130, Accounting for Impressive Dx Inflection

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 289

01/17/2014

Daily Note

Pages: 9

Impressive Investor Day - Multiple New Products

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 290

01/17/2014

Daily Note

Pages: 9

Impressive Investor Day - Multiple New Products - NeoPrep Automated Sample Pre Device Stands Out - Diagnostics Theme Accelerating

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 291

10/22/2013

Company Report

Pages: 11

3Q13 Beat & Raise Driven By Impressive System Sales Again - Bona Fide Applied Market Inflection Encouraging - Upping Estimates - Raising PT to $72

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 292

10/15/2013

Company Report

Pages: 7

Raising Estimates and Upping PT

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 293

10/15/2013

Industry Report

Pages: 10

Technical Analysis - Biotech Stocks Ignored and Oversold, Offering Good Entry

Provider: Drexel Hamilton, LLC

Analyst: SINE B

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 294

09/26/2013

Daily Note

Pages: 7

Diagnostics Update: FMI IPO Perspective - Harmless Roche & PACB Partnership - iGenomics Remains the Anomaly in Pre-Natal - Reaffirm N

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 295

08/22/2013

Daily Note

Pages: 11

Updating Pre-Natal Cheatsheet Post Wedbush LS Conference - Average Risk Market Less Penetrated & Chinese Market Appears Stronger - Maintain N

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 296

07/24/2013

Company Report

Pages: 12

Solid 2Q13 Beat & Raise Driven By Strong HiSeq Systems & Upgrades - Applied Markets Solid - Warming To Leverage Story & ALL Tuck-In - PT to $60

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 297

07/16/2013

Company Report

Pages: 8

2Q13 Preview - Expecting Solid Top Line and So-So EPS

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 298

05/03/2013

Daily Note

Pages: 10

Updating Pre-Natal Model & Cheatsheet - Adjusting Verinata Model Lower After Green Journal Article - Estimates Unchanged - Maintain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 299

04/23/2013

Company Report

Pages: 11

1Q13 Recap - Sequencing Business Solid - Array Segment Improvement Helps Top Our Street-High Rev View

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 300

04/17/2013

Company Report

Pages: 11

Expecting Solid 1Q13 Results - Encouraged by Verinata In- Network Progress and Unfazed by LIFE Deal - Maintaining NEUTRAL Rating

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party